Is hepatitis delta underestimated?
HBV co-infection
HDV epidemiology
cirrhosis
hepatitis D
hepatocellular carcinoma
prevalence
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
22
02
2021
accepted:
22
02
2021
entrez:
22
6
2021
pubmed:
23
6
2021
medline:
29
6
2021
Statut:
ppublish
Résumé
Hepatitis D virus may be underestimated because it is a significant problem in HBsAg-positive patients, especially those who inject drugs, have HIV or HCV co-infections and/or live in certain endemic regions. In the past few decades, the prevalence of HDV was expected to have decreased as a result of improvements in public healthcare policies and universal HBV vaccination programs. However, HDV has continued to spread in low-income countries, with local outbreaks and migration to less endemic areas, so that its prevalence has remained stable or even increased in certain regions. As a result, research has been focused on the epidemiology of HDV. Contradicting data from three large recent meta-analyses have reported that the prevalence of HDV may be between 0.16% and 1.00% in the global general population, and 4.5% and 14.6% in HBsAg-positive patients, with an estimated 12 to 70 million HDV patients worldwide. The exact prevalence and estimated number of HDV patients is still a subject of debate for several reasons, including the unreliable assessment of the infection and a lack of real-world screening. HDV infection is associated with an increased risk of progression to cirrhosis and the development of HCC compared to patients with HBV mono-infection, a risk which is even higher in patients with HIV co-infection. Morbidity and mortality from HDV-related cirrhosis should not be overlooked. In conclusion, hepatitis D virus is probably underestimated and certainly underdiagnosed, and screening for HDV should be performed in all HBsAg-positive patients in clinical practice.
Substances chimiques
Hepatitis B Surface Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-44Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Wedemeyer H. The burden of hepatitis D - defogging the epidemiological horizon. J Hepatol. 2020;73(3):493-495. https://doi.org/10.1016/j.jhep.2020.06.037
Orpha.net. https://www.orpha.net/
Yurdaydin C, Abbas Z, Buti M, et al. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. J Hepatol. 2019;70(5):1008-1015. https://doi.org/10.1016/j.jhep.2018.12.022
Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18(12):997-1003. https://doi.org/10.1136/gut.18.12.997
Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin Liver Dis. 2012;32(03):211-219. https://doi.org/10.1055/s-0032-1323626
Rizzetto M, Hepatitis D. Virus: Introduction and Epidemiology. Cold Spring Harb Perspect Med. 2015;5(7):a021576. https://doi.org/10.1101/cshperspect.a021576
Tassopoulos NC, Koutelou MG, Papatheodoridis GV, Kalantzakis YS, Hatzakis AE. Acute delta hepatitis in Greek parenteral drug abusers. Prog Clin Biol Res. 1993;382:221-227. http://www.ncbi.nlm.nih.gov/pubmed/8502685
Vlachogiannakos J, Papatheodoridis GV. New epidemiology of hepatitis delta. Liver Int. 2020;40(S1):48-53. https://doi.org/10.1111/liv.14357
WHO. Global hepatitis report, 2017.
Chen H-Y, Shen D-T, Ji D-Z, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019;68(3):512-521. https://doi.org/10.1136/gutjnl-2018-316601
Shen D-T, Ji D-Z, Chen H-Y, Goyal H, Pan S, Xu H-G. Hepatitis D: not a rare disease anymore: global update for 2017-2018. Gut. 2020;69(4):786-788. https://doi.org/10.1136/gutjnl-2019-318691
Wedemeyer H, Negro F. Devil hepatitis D: an orphan disease or largely underdiagnosed? Gut. 2019;68(3):381-382. https://doi.org/10.1136/gutjnl-2018-317403
Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221(10):1677-1687. https://doi.org/10.1093/infdis/jiz633
Miao Z, Pan Q. Revisiting the estimation of hepatitis D global prevalence. J Hepatol. 2020;73(5):1279-1280. https://doi.org/10.1016/j.jhep.2020.05.019
Perez-Vargas J, Amirache F, Boson B, et al. Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo. Nat Commun. 2019;10(1):2098. https://doi.org/10.1038/s41467-019-10117-z
Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73(3):523-532. https://doi.org/10.1016/j.jhep.2020.04.008
Stockdale AJ, Chaponda M, Beloukas A, et al. Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Heal. 2017;5(10):e992-e1003. https://doi.org/10.1016/S2214-109X(17)30298-X
WHO. Global health sector strategy on viral hepatitis 2016-2021.
Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398. https://doi.org/10.1016/j.jhep.2017.03.021
Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. https://doi.org/10.1007/s12072-015-9675-4
Manesis EK, Vourli G, Dalekos G, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013;59(5):949-956. https://doi.org/10.1016/j.jhep.2013.07.005
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599. https://doi.org/10.1002/hep.29800
Kushner T, Serper M, Kaplan DE. Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes. J Hepatol. 2015;63(3):586-592. https://doi.org/10.1016/j.jhep.2015.04.025
Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378(9785):73-85. https://doi.org/10.1016/S0140-6736(10)61931-9
Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7(1):31-40. https://doi.org/10.1038/nrgastro.2009.205
Fattovich G. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut. 2000;46(3):420-426. https://doi.org/10.1136/gut.46.3.420
Alfaiate D, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J Hepatol. 2020;73(3):533-539. https://doi.org/10.1016/j.jhep.2020.02.030
Benegiamo G, Vinciguerra M, Guarnieri V, Niro GA, Andriulli A, Pazienza V. Hepatitis delta virus induces specific DNA methylation processes in Huh-7 liver cancer cells. FEBS Lett. 2013;587(9):1424-1428. https://doi.org/10.1016/j.febslet.2013.03.021
Diaz G, Engle RE, Tice A, et al. Molecular signature and mechanisms of hepatitis D virus-associated hepatocellular carcinoma. Mol Cancer Res. 2018;16(9):1406-1419. https://doi.org/10.1158/1541-7786.MCR-18-0012
Ferrante ND, Lo RV. Epidemiology, natural history, and treatment of hepatitis delta virus infection in HIV/hepatitis B virus coinfection. Curr HIV/AIDS Rep. 2020;17(4):405-414. https://doi.org/10.1007/s11904-020-00508-z